Sex differences in thrombosis as it affects acute ischemic stroke

• Published in: Neurobiology of disease Vol. 165; p. 105647
• Main Authors: Nimjee, Shahid M., Akhter, Asad S., Zakeri, Amanda, Herson, Paco S.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2022; Elsevier
• Subjects: Brain Ischemia - drug therapy; Brain Ischemia - therapy; Estrogen; Female; Fibrinolytic Agents - therapeutic use; Humans; Ischemic stroke; Ischemic Stroke - complications; Ischemic Stroke - therapy; Male; Sex Characteristics; Sex-differences; Thrombosis; Thrombosis - drug therapy; Tissue Plasminogen Activator - therapeutic use; Treatment Outcome; von Willebrand factor; Ischemic stroke; Sex-differences; Thrombosis; von Willebrand factor; Estrogen
• ISSN: 0969-9961; 1095-953X
• DOI: 10.1016/j.nbd.2022.105647

Ischemic stroke is a devastating health problem, affecting approximately 800,000 patients in the US every year, making it the leading cause of combined death and disability in the country. Stroke has historically been thought of as predominantly impacting men, however it is becoming increasingly clear that stroke affects women to a greater degree than men. Indeed, women have worse outcomes compared to men following ischemic stroke. Recent clinical advances have shown great promise in acute stroke therapy, with the use of mechanical endovascular thrombectomy (with and without recombinant tissue plasminogen activator; rtPA) greatly improving outcomes. This observation makes it clear that removal of clots and reperfusion, either mechanically or pharmacologically, is critical for improving outcomes of patients following acute ischemic stroke. Despite these promising advances, long-term neurological sequelae persist in the post-stroke population. This review focuses on mechanisms of thrombosis (clot formation) as it pertains to stroke and important sex differences in thrombosis and responses to treatment. Finally, we describe recent data related to new therapeutic approaches to thrombolysis, with a particular focus on von Willebrand Factor (vWF).